Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 5/20 | 0.39 |
| ▸ | RXRB | P28702 | 5/20 | 0.39 |
| ▸ | RXRG | P48443 | 5/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850155 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2849040 | 0.91 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2846305 | 0.88 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2846307 | 0.88 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2852869 | 0.88 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2852606 | 0.87 | APP (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2850235 | 0.86 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2848843 | 0.85 | KCNH2 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2848283 | 0.83 | KCNH2 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2847151 | 0.83 | APP (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010138901-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE | BIOGEN IDEC MA INC (US) | 2010-12-02 | — | — | WO | claimed |
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | PSEN1 15/4885PSEN2 26/4885APH1B 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.